May 25, 2020
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)(1)
Apr 08, 2020
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME(TM) Technology
Apr 06, 2020
Pulmonary Fibrosis Foundation Statement on COVID-19
Mar 16, 2020
Insmed Provides Business Update
Mar 09, 2020
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Mar 04, 2020
Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease
Mar 04, 2020
Pulmonary Fibrosis Foundation Launches Industry Consortium To Identify Biomarkers In Pulmonary Fibrosis
Jan 14, 2020
Rx Globally Patented Non-Steroidal Nasal Spray for All Lung Diseases including Pulmonary Fibrosis, CF, COPD, Unmet Needs with No Known Side Effects that can also be used to Deliver Antivirals, Antimicrobials, Insulin, and other Drugs
Nov 20, 2019
New Report Reveals Major Gaps in Quality of Care for Canadians with Rare Lung Disease
Nov 07, 2019
New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
Nov 04, 2019
NIH Awards Major Grant In Pulmonary Fibrosis Research
Oct 21, 2019
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
Oct 14, 2019
VIDA Partners With TeraRecon, Inc. For Distribution Of AI-Powered Lung Analysis
Oct 10, 2019
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Oct 09, 2019
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype(1)
Sep 09, 2019
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Sep 06, 2019
FDA approves first treatment for patients with rare type of lung disease
Jul 25, 2019
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
May 30, 2019
Pulmonary Fibrosis Patient Registry Research Presented At American Thoracic Society Conference
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD